Identification of tumor suppressive role of microRNA-132 and its target gene in tumorigenesis of prostate cancer

Li,Shun-Lai; Sui,Ying; Sun,Jie; Jiang,Ting-Qi; Dong,Gang

doi:10.3892/ijmm.2018.3421

Identification of tumor suppressive role of microRNA-132 and its target gene in tumorigenesis of prostate cancer

Authors:
- Shun-Lai Li
- Ying Sui
- Jie Sun
- Ting-Qi Jiang
- Gang Dong
View Affiliations

Affiliations: Department of Urology, The Fifth People's Hospital of Jinan, Jinan, Shandong 250012, P.R. China, Tianqiao Hospital in Jinan of Shandong, Jinan, Shandong 250022, P.R. China
Published online on: January 23, 2018 https://doi.org/10.3892/ijmm.2018.3421
Pages: 2429-2433

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous literature exists on the role of microRNA (miR)-132 in initiation and progression of various malignancies. In this study, we aimed at understanding the relationship of miR-132 of prostate tumorigenesis. We collected 32 prostate cancer tissues and adjacent non-cancerous controls, and detected the expression level of miR-132. Then the miRNA database was searched online and luciferase assay perform to understand the regulatory relationship between miR-132 and E2F5. Moreover, we also conducted real-time PCR and western blot analysis to study the mRNA and protein expression level of E2F5 among different groups (cancerous tissue, n=32; non-cancerous tissue, n=32) or cells treated with scramble control, miR-132 mimics, E2F5 siRNA and miR-132 inhibitors. miR-132 was upregulated in cancerous tissues of prostate cancer patients. E2F5 was the target of miR-132, and negative regulatory relationship between miR-132 and E2F5 was also confirmed by luciferase assay. The mRNA and protein expression level of E2F5 increased in cancerous tissue group. miR-132 decreased the expression of E2F5 in prostate cancer cells, and introduction of miR-132 reduced the viability and E2F5 and promoted the viability of prostate cancer cells. miR-132 inhibited apoptosis and E2F5 accelerated apoptosis. In conclusion, miR-132 was upregulated in cancerous tissue of prostate cancer. E2F5 was a direct target of miR-132, and downregulation of E2F5 caused by upregulation of miR-132 may contribute to the tumorigenesis of prostate cancer.

View Figures

View References

1	Crawford ED: Epidemiology of prostate cancer. Urology. 62(Suppl 1): 3–12. 2003. View Article : Google Scholar
2	Coughlin SS and Hall IJ: A review of genetic polymorphisms and prostate cancer risk. Ann Epidemiol. 12:182–196. 2002. View Article : Google Scholar : PubMed/NCBI
3	Witte JS: Prostate cancer genomics: towards a new under-standing. Nat Rev Genet. 10:77–82. 2009. View Article : Google Scholar
4	Kim TM, Yim SH, Shin SH, Xu HD, Jung YC, Park CK, Choi JY, Park WS, Kwon MS, Fiegler H, et al: Clinical implication of recurrent copy number alterations in hepatocellular carcinoma and putative oncogenes in recurrent gains on 1q. Int J Cancer. 123:2808–2815. 2008. View Article : Google Scholar : PubMed/NCBI
5	Chen HZ, Tsai SY and Leone G: Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer. 9:785–797. 2009. View Article : Google Scholar : PubMed/NCBI
6	Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, Young RA and Dynlacht BD: E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev. 16:245–256. 2002. View Article : Google Scholar : PubMed/NCBI
7	Han S, Park K, Bae BN, Kim KH, Kim HJ, Kim YD and Kim HY: E2F1 expression is related with the poor survival of lymph node-positive breast cancer patients treated with fluorouracil, doxorubicin and cyclophosphamide. Breast Cancer Res Treat. 82:11–16. 2003. View Article : Google Scholar : PubMed/NCBI
8	Reimer D, Sadr S, Wiedemair A, Stadlmann S, Concin N, Hofstetter G, Müller-Holzner E, Marth C and Zeimet AG: Clinical relevance of E2F family members in ovarian cancer - an evaluation in a training set of 77 patients. Clin Cancer Res. 13:144–151. 2007. View Article : Google Scholar : PubMed/NCBI
9	Eymin B, Gazzeri S, Brambilla C and Brambilla E: Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma. Oncogene. 20:1678–1687. 2001. View Article : Google Scholar : PubMed/NCBI
10	Lee J, Park CK, Park JO, Lim T, Park YS, Lim HY, Lee I, Sohn TS, Noh JH, Heo JS, et al: Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy. Clin Cancer Res. 14:82–88. 2008. View Article : Google Scholar : PubMed/NCBI
11	Saugstad JA: MicroRNAs as effectors of brain function with roles in ischemia and injury, neuroprotection, and neurodegeneration. J Cereb Blood Flow Metab. 30:1564–1576. 2010. View Article : Google Scholar : PubMed/NCBI
12	Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
13	Coppola V, De Maria R and Bonci D: MicroRNAs and prostate cancer. Endocr Relat Cancer. 17:F1–F17. 2010. View Article : Google Scholar
14	Fang YX and Gao WQ: Roles of microRNAs during prostatic tumorigenesis and tumor progression. Oncogene. 33:135–147. 2014. View Article : Google Scholar
15	Casanova-Salas I, Rubio-Briones J, Fernández-Serra A and López-Guerrero JA: miRNAs as biomarkers in prostate cancer. Clin Transl Oncol. 14:803–811. 2012. View Article : Google Scholar : PubMed/NCBI
16	Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006. View Article : Google Scholar : PubMed/NCBI
17	Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, et al: Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 68:6162–6170. 2008. View Article : Google Scholar : PubMed/NCBI
18	Theodore SC, Davis M, Zhao F, Wang H, Chen D, Rhim J, Dean-Colomb W, Turner T, Ji W, Zeng G, et al: MicroRNA profiling of novel African American and Caucasian prostate cancer cell lines reveals a reciprocal regulatory relationship of miR-152 and DNA methyltranferase 1. Oncotarget. 5:3512–3525. 2014. View Article : Google Scholar : PubMed/NCBI
19	Zhao J, Wu XY, Ling XH, Lin ZY, Fu X, Deng YH, He HC and Zhong W: Analysis of genetic aberrations on chromosomal region 8q21-24 identifies E2F5 as an oncogene with copy number gain in prostate cancer. Med Oncol. 30:4652013. View Article : Google Scholar : PubMed/NCBI
20	Agarwal C, Dhanalakshmi S, Singh RP and Agarwal R: Inositol hexaphosphate inhibits growth and induces G1 arrest and apoptotic death of androgen-dependent human prostate carcinoma LNCaP cells. Neoplasia. 6:646–659. 2004. View Article : Google Scholar : PubMed/NCBI
21	Lau P, Bossers K, Janky R, Salta E, Frigerio CS, Barbash S, Rothman R, Sierksma AS, Thathiah A, Greenberg D, et al: Alteration of the microRNA network during the progression of Alzheimer's disease. EMBO Mol Med. 5:1613–1634. 2013. View Article : Google Scholar : PubMed/NCBI
22	Jin W, Reddy MA, Chen Z, Putta S, Lanting L, Kato M, Park JT, Chandra M, Wang C, Tangirala RK, et al: Small RNA sequencing reveals microRNAs that modulate angiotensin II effects in vascular smooth muscle cells. J Biol Chem. 287:15672–15683. 2012. View Article : Google Scholar : PubMed/NCBI
23	Zhang ZG, Chen WX, Wu YH, Liang HF and Zhang BX: miR-132 prohibits proliferation, invasion, migration, and metastasis in breast cancer by targeting HN1. Biochem Biophys Res Commun. 454:109–114. 2014. View Article : Google Scholar : PubMed/NCBI
24	Zheng YB, Luo HP, Shi Q, Hao ZN, Ding Y, Wang QS, Li SB, Xiao GC and Tong SL: miR-132 inhibits colorectal cancer invasion and metastasis via directly targeting ZEB2. World J Gastroenterol. 20:6515–6522. 2014. View Article : Google Scholar : PubMed/NCBI